Skip to main content
Sartorius Stedim Biotech logo

Sartorius Stedim Biotech — Investor Relations & Filings

Ticker · DIM ISIN · FR0013154002 LEI · 52990006IVXY7GCSSR39 PA Manufacturing
Open in API
Filings indexed 425 across all filing types
Latest filing 2024-07-18 Interim / Quarterly Rep…
Country FR France
Listing PA DIM

About Sartorius Stedim Biotech

https://www.sartorius.com/en

Sartorius Stedim Biotech is a leading international provider of equipment and services for the biopharmaceutical industry. The company offers integrated solutions that support the entire lifecycle of drug development and manufacturing, from research and development to quality assurance and commercial production. Its comprehensive portfolio includes technologies for filtration, fluid management, fermentation, cell culture, and purification. Key products encompass bioreactors, single-use systems, process filtration equipment, cell culture media, and data analytics software. Sartorius Stedim Biotech enables its customers to develop and manufacture biotech medications, including cell and gene therapies, more efficiently and safely, helping to accelerate the translation of scientific discoveries into patient care.

Recent filings

Filing Released Lang Actions
Half yearly financial reports and audit reports/limited reviews
Interim / Quarterly Report Classification · 1% confidence The document is a 'Rapport financier semestriel' (Half-year financial report) for Sartorius Stedim Biotech for the first half of 2024. It contains detailed financial statements, including income statements, balance sheet data, and management analysis of the results. As it covers a period shorter than a full fiscal year and provides substantive financial data, it is classified as an Interim/Quarterly Report. H1 2024
2024-07-18 French
Sartorius Stedim Biotech SA: Sartorius Stedim Biotech adjusts its guidance for fiscal year 2024 and presents results for H1 2024
Earnings Release Classification · 1% confidence The document provides a detailed summary of financial performance for the first half (H1) of the fiscal year 2024, including sales revenue, order intake, EBITDA, net profit, and key balance sheet items as of June 30, 2024. Crucially, it also includes an 'Outlook for fiscal 2024 de-risked' section where the company adjusts its guidance for the full year based on the H1 results and current market conditions. This structure—reporting on a completed interim period (H1) and providing updated full-year guidance—is characteristic of an Interim/Quarterly Report (IR). It is more comprehensive than a simple Earnings Release (ER) which usually only provides highlights, and it is not a full Annual Report (10-K). The presence of specific financial figures for H1 2024 confirms it is a period report. H1 2024
2024-07-18 English
Sartorius Stedim Biotech SA: Sartorius Stedim Biotech ajuste ses prévisions pour l’exercice 2024 et présente ses résultats pur le premier semestre 2024
Earnings Release Classification · 1% confidence The document is a press release titled "Sartorius Stedim Biotech ajuste ses prévisions pour l'exercice 2024 et présente ses résultats pur le premier semestre 2024" (Sartorius Stedim Biotech adjusts its forecast for fiscal year 2024 and presents its results for the first half of 2024). It details financial performance metrics (revenue, EBITDA, net income) for the first half of the year (H1 2024) and subsequently provides an adjusted forecast for the full fiscal year 2024. This structure—reporting on a completed interim period (H1) and updating future guidance—is characteristic of an Earnings Release (ER) or an Interim Report (IR). Since it explicitly covers the 'premier semestre' (first half) results comprehensively, it fits the definition of an Interim / Quarterly Report (IR) better than just an Earnings Release (ER), which usually contains only key highlights. However, the document focuses heavily on the *adjustment of forecasts* based on the H1 performance and market outlook, which is a core component of an Earnings Release. Given the comprehensive nature of the financial data presented (including balance sheet items like equity and debt ratios, and detailed income statement figures), it leans towards a comprehensive interim report. In many contexts, a detailed H1 report that includes guidance updates is classified as an Interim Report (IR). If it were purely a brief announcement of results, ER would be appropriate. Since it provides detailed financial figures for the first half, IR is the most fitting category. H1 2024
2024-07-18 French
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL' and explicitly references French commercial code (Article L 233-8-II) and AMF regulations. It provides a table detailing the total number of shares, theoretical voting rights, and net voting rights as of a specific date (June 30, 2024). This content directly relates to the official declaration of voting rights and capital structure, which aligns best with the 'Declaration of Voting Results & Voting Rights Announcements' category (DVA). It is not an AGM presentation, a full annual report (10-K), or a simple dividend notice.
2024-07-02 English
Sartorius Stedim Biotech SA: DECLARATION RELATIVE AU NOMBRE D’ACTIONS ET DE DROITS DE VOTE COMPOSANT LE CAPITAL SOCIAL
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'DECLARATION RELATIVE AU NOMBRE D'ACTIONS ET DE DROITS DE VOTE COMPOSANT LE CAPITAL SOCIAL' (Declaration relative to the number of shares and voting rights comprising the share capital). It explicitly references French commercial code (Article L 233-8-II du Code de commerce) and AMF regulations, and provides a table detailing the total number of shares and theoretical/net voting rights as of a specific date (30 Juin 2024). This content directly relates to official disclosures regarding the company's capital structure and voting rights, which aligns best with the 'Declaration of Voting Results & Voting Rights Announcements' category (DVA), as it is a formal declaration about the current voting rights structure.
2024-07-02 French
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
Regulatory Filings Classification · 1% confidence The document is explicitly titled "Half-year liquidity contract statement for Sartorius Stedim Biotech" and provides detailed figures regarding share holdings, cash balances, and trading activity (buy/sell executions and volumes) related to a liquidity contract, dated June 30th, 2024, referencing the previous statement from December 31st, 2023. This type of periodic disclosure regarding market making or liquidity provision activities, often mandated by local regulators (like the AMF mentioned), is a specific type of regulatory disclosure. It is not a full Annual Report (10-K), an Earnings Release (ER), or a standard Interim Report (IR), which focus on comprehensive financial statements. It is a specialized disclosure related to market operations. Given the options, this specialized, periodic report on market activity best fits under the general 'Regulatory Filings' (RNS) category, as there is no specific code for 'Liquidity Statement'. It is a formal, periodic regulatory disclosure.
2024-07-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.